• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Rilonacept may lower pericarditis recurrence in patients with relapsing pericarditis

byHarsh ShahandDeepti Shroff Karhade
December 4, 2020
in Chronic Disease
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Rilonacept significantly lowered pericarditis recurrence risk compared to placebo.

2. Rilonacept rapidly resolved recurrent pericarditis episodes in at risk patients.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Recurrent pericarditis is characterized by chronic and debilitating pericardial inflammation with limited treatment options such as glucocorticoids. However, the nonspecific immunosuppression property of glucocorticoids is particularly concerning for long-term use. Alternatively, interleukin-1 inhibition is a potential therapeutic for patients with systemic inflammation including pericarditis. As such, this study evaluated whether rilonacept, an interleukin-1α and interleukin-1β cytokine trap, could reduce the risk of pericarditis recurrence. The study determined rilonacept significantly lowered pericarditis recurrence risk, while rapidly resolving pericarditis episodes. The randomized control trial was limited by the randomized-withdrawal trial study design. Nonetheless, this study’s results are significant, and its findings highlight an effective treatment reduce recurrent pericarditis risk in patients with rilonacept treatment.

Click to read the study in NEJM

Relevant Reading: Effect of Anakinra on Recurrent Pericarditis Among Patients with Colchicine Resistance and Corticosteroid Dependence: The AIRTRIP Randomized Clinical Trial

RELATED REPORTS

Colchicine not beneficial after acute myocardial infarction for reducing cardiovascular events

#VisualAbstract: Long-term Colchicine Does Not Reduce Recurrent Events Following Ischemic Stroke

Long-term colchicine does not reduce recurrent events following ischemic stroke

In-Depth [randomized controlled trial]: This randomized-withdrawal trial enrolled 86 participants in a multicenter study in four countries. Participants included in the study were ≥ 12 years of age with recurrent pericarditis, presented with pericarditis during at least a second recurrence, and received combinatorial treatment of nonsteroidal anti-inflammatory drugs (NSAIDs), colchicine, or glucocorticoids. Participants with a pain score of less than 4 on a numerical rating scale were excluded from this study. The participants were randomized in a 1:1 ratio to weekly receive rilonacept or placebo, respectively. The primary endpoint was recurrence events. A recurrence event was defined as return of pericarditis pain and an increased in C-reactive protein (CRP) levels. During the run-in period, the median time to pain response was 5 days (95% confidence interval [CI], 4 to 6) and the median time to CRP level normalization was 7 days (95% CI, 5 to 8). Out of the enrolled 86 participants, 61 participants completed the run-in period and underwent randomization. At the end of the randomized-withdrawal period, rilonacept led to a significantly lower pericarditis recurrence risk compared to the placebo (hazard ratio, 0.04; 95% CI, 0.01 to 0.18; P<0.001). During this period, 2 of 30 participants (7%) in the rilonacept group had a pericarditis recurrence compared to 23 of 31 patients (74%) in the control group. Additionally, 17 of 21 participants (81%) had a persistent clinical response at 16 weeks in the rilonacept group compared to 4 of 20 participants (20%) in the control group (difference, 61; 95% CI, 37 to 85; P<0.001). Furthermore, 17 of 21 participants (81%) presented with absent or minimal pericarditis symptoms in the rilonacept group compared to 5 of 20 participants (25%) in the control group (difference, 56; 95% CI, 31 to 81; P<0.001). Finally, injection-site reactions and upper respiratory tract infections were the most common adverse events. Overall, 29 participants (34%) and 7 participants (23%), all whom received rilonacept, had injection-site reactions and upper respiratory tract infections, respectively. Taken together, rilonacept significantly lowered the risk of pericarditis recurrence in at-risk patients.

Image: PD

©2020 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

 

Tags: colchicineinterleukin-1 inhibitionNSAIDpericarditisrilonacept
Previous Post

No difference in survival after laparoscopic versus open liver resection for colorectal metastases

Next Post

Neuraxial anesthesia associated with decreased 30-day all-cause mortality for patients undergoing lower limb revascularization

RelatedReports

PCI not superior to medical therapy alone in stable coronary disease: The COURAGE study
Cardiology

Colchicine not beneficial after acute myocardial infarction for reducing cardiovascular events

March 3, 2025
#VisualAbstract: Long-term Colchicine Does Not Reduce Recurrent Events Following Ischemic Stroke
StudyGraphics

#VisualAbstract: Long-term Colchicine Does Not Reduce Recurrent Events Following Ischemic Stroke

August 15, 2024
Stroke expansion following intra-arterial therapy may explain worse outcomes
Cardiology

Long-term colchicine does not reduce recurrent events following ischemic stroke

August 7, 2024
Mild-to-moderate hypertriglyceridemia associated with higher risk of acute pancreatitis
Chronic Disease

Prophylactic pancreatic stent plus indomethacin reduces rates of pancreatitis following endoscopic retrograde cholangiopancreatography

March 27, 2024
Next Post

Neuraxial anesthesia associated with decreased 30-day all-cause mortality for patients undergoing lower limb revascularization

E-interventions linked to short-term reduction in alcohol consumption in college students

Acamprosate found to be one of few effective and tolerable interventions for alcohol dependence

Quick Take: Long-term outcome of surgery versus conservative management for recurrent and ongoing complaints after an episode of diverticulitis

Laparoscopic sigmoid resection for recurrent diverticulitis associated with higher quality of life scores

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Structured exercise intervention improves survival in colon cancer patients
  • #VisualAbstract: Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer
  • Cerebral embolic protection does not decrease stroke incidence in TAVI patients
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.